Noven recalls thousands of hormone patches that failed to meet specifications

According to FDA Enforcement reports, Noven is once again recalling patches that don't meet specifications. (FDA)

Just weeks after receiving a close-out for a 2016 warning letter, adhesive patch maker Noven began recalling more than 130,000 boxes of its estradiol adhesive patches in two dose formulations.

Noven in May started a recall of two lots, or 70,870 boxes of its 0.0375 mg/day patches and two lots, consisting of 61,960 boxes of the 0.1 mg/day dose of Minivelle (estradiol transdermal system).

According to an FDA Enforcement report, the class II recall was initiated because the patches failed to meet specifications for their sheer adhesive properties.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

RELATED: FDA issues Noven another warning letter for factory that produces ADHD patches

The patches were manufactured at Noven’s plant in Miami, Florida, a facility that has been issued FDA warning letters three times: in 2008, 2011 and then again in 2016.

Noven, a standalone operating subsidiary of Japan-based Hisamitsu Pharmaceuticals, received a close-out for the 2016 letter in April, just few weeks ahead of starting recalls.

The 2016 warning letter found Noven's operating procedures were not up to par. It said the FDA was concerned that the plant’s “unsound methods could be masking product failures.”

RELATED: Noven ADHD patches in short supply after recall

Before getting that warning, Noven recalled tens of thousands of boxes of its Daytrana patches from the market because of issues over peeling away a protective liner to deliver the ADHD drug. The recall resulted in a nationwide shortage of the patches.


Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.